Discontinued — last reported Q4 '25
Products & Services · Other Intangibles, Net
Keytruda Qlex — Other Intangibles, Net
Merck & Co. Keytruda Qlex — Other Intangibles, Net increased by 31.9% to $930.00M in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ3 2025
Last reportedQ4 2025
Rolls up toOther intangible assets—net
How to read this metric
An increase suggests ongoing investment in product-related intellectual property, while a decrease reflects amortization or impairment of these assets.
Detailed definition
This represents the net book value of intangible assets associated with a specific product line, excluding primary paten...
Peer comparison
Standard across life sciences firms that acquire product rights or specialized technology to bolster their portfolio.
Metric ID:
mrk_segment_keytruda_qlex_other_intangibles_netHistorical Data
2 periods
| Q3 '25 | Q4 '25 | |
|---|---|---|
| Value | $705.00M | $930.00M |
| QoQ Change | — | +31.9% |
Range$705.00M – $930.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s keytruda qlex — other intangibles, net?
- Merck & Co. (MRK) reported keytruda qlex — other intangibles, net of $930.00M in Q4 2025.
- What does keytruda qlex — other intangibles, net mean?
- The net value of non-patent intangible assets, such as licenses or distribution rights, held for this product line.